Video
Dr. McKay Discusses Advances in the Treatment of Metastatic RCC
Author(s):
Rana R. McKay, MD, medical oncologist, assistant professor, Moores Cancer Center at the University of California, San Diego, discusses advances in the treatment of metastatic renal cell carcinoma.
Rana R. McKay, MD, medical oncologist, assistant professor, Moores Cancer Center at the University of California, San Diego, discusses advances in the treatment of metastatic renal cell carcinoma (RCC).
One of the most influential studies over the past few years has been the CheckMate-025 study in patients with metastatic clear cell RCC, says McKay. This was the first time that a second-line treatment was shown to improve overall survival in this population.
Studies with cabozantinib (Cabometyx), ipilimumab (Yervoy) plus nivolumab (Opdivo), and sunitinib (Sutent) have also enriched the treatment landscape of metastatic RCC, McKay adds.
